Post-feeding hyperammonaemia in patients with transjugular intrahepatic portosystemic shunt and liver cirrhosis: role of small intestinal ammonia release and route of nutrient administration

M Plauth, A-E Roske, P Romaniuk, E Roth, R Ziebig, H Lochs

Abstract

Background—Hyperammonaemia is a pathogenetic factor for hepatic encephalopathy that may be augmented after a transjugular intrahepatic portosystemic shunt (TIPS). Experimental data suggest that hyperammonaemia may be caused to a large extent by metabolism of small intestinal enteroctyes rather than colonic bacteria.

Aims—To evaluate if ammonia release and glutamine metabolism by small intestinal mucosa contribute to hyperammonaemia in vivo in patients with liver cirrhosis.

Methods—Using TIPS to examine mesenteric venous blood, we measured mesenteric venous-arterial concentration differences in ammonia and glutamine in patients with liver cirrhosis before, during, and after enteral (n=8) or parenteral (n=8) isonitrogenous infusion of a glutamine containing amino acid solution.

Results—During enteral nutrient infusion, ammonia release increased rapidly compared with the post-absorptive state (65 (58–73) vs 107 (95–119) μmol/l after 15 min; mean (95% confidence interval)) in contrast with parenteral infusion (50 (41–59) vs 62 (47–77) μmol/l). This resulted in a higher portal ammonia load (29 (21–36) vs 14 (8–21) μmol/l/240 minutes) and a higher degree of systemic hyperammonaemia (14 (11–17) vs 9 (6–12) μmol/l/240 minutes) during enteral than parenteral infusion. The mesenteric venous-arterial concentration difference in glutamine changed from net uptake to release at the end of the enteral infusion period (−100 (−58 to −141) vs 31 (−47–110) μmol/l) with no change during parenteral nutrition.

Conclusions—These data suggest that small intestinal metabolism contributes to post-feeding hyperammonaemia in patients with cirrhosis. When artificial nutrition is required, parenteral nutrition may be superior to enteral nutrition in patients with portosystemic shunting because of the lower degree of systemic hyperammonaemia.

Despite the emergence of other potential pathogenetic mechanisms, hyperammonaemia is still regarded as a relevant factor in the pathogenesis of hepatic encephalopathy. The pathogenetic concept that metabolism of colonic bacteria is the major source of the portal venous ammonia load failed to provide a full understanding of phenomena such as the “germ free paradox”. This term was coined after the observation that hepatic coma and hyperammonaemia occurred in germ free animals following construction of an Eck fistula or after hepatectomy. These phenomena, however, could be explained by the observation that the small intestinal mucosa normally extracts glutamine from arterial blood for metabolism of enterocytes and releases considerable quantities of ammonia into the portal vein. From studies in catheterised pigs or dogs, it was estimated that amino acid metabolism of the small intestinal mucosa is a relevant source of portal ammonia that cannot be suppressed by antibiotics or lactulose.

Therapeutic interventions aimed at reduction in portal pressure by surgical or transjugular construction of a portosystemic shunt are accompanied by an increase in the frequency and/or severity of episodes of hepatic encephalopathy. We hypothesised that following a transjugular intrahepatic portosystemic shunt (TIPS), small intestinal ammonia production may lead to a higher degree of systemic hyperammonaemia when nutrition is given by the enteral rather than the parenteral route. This could be clinically relevant as enteral nutrition has generally been regarded as preferable to parenteral nutrition in patients with decompensated chronic liver disease. Furthermore, because of the poor accessibility of the portal or mesenteric veins, human data on intestinal glutamine and ammonia metabolism are available only for the fasting state during elective abdominal surgery without infusion of substrates; there are no data under postprandial or parenterally fed conditions in patients with liver cirrhosis. Therefore, we have investigated in patients with TIPS whether the small intestine is a relevant source for systemic post-feeding hyperammonaemia and to what extent post-feeding hyperammonaemia

Abbreviations used in this paper: AA, amino acid; ALD, alcoholic liver disease; AUC, area under the curve; PBC, primary biliary cirrhosis; SMV, superior mesenteric vein; TIPS, transjugular intrahepatic portosystemic shunt.
is affected by the supply of nitrogenous nutrients via the enteral compared with the parenteral route.21

**Methods**

**Patients**

In 16 consecutive patients with liver cirrhosis of alcoholic or autoimmune aetiology (table 1), a TIPS was inserted for refractory ascites (n=1) or for recurrent variceal bleeding (n=15). Patients were studied either on the day of TIPS insertion (n=5/8 in the enteral group and n=3/8 in the parenteral group) or during routine portography for examination of TIPS patency. All patients were in a stable condition (>15 days since the last haemorrhage, transaminase <3 times the upper limit of normal). Before the study, an oral decontamination protocol was instituted for 72 hours, consisting of tobramycin 80 mg four times daily, colistin 100 mg four times daily and amphotericin B 500 mg four times daily to reduce ammonia production from intestinal bacteria.22 All patients gave written informed consent to participate in the study which was reviewed by the Charité ethics committee and which conformed to the guidelines of the 1975 Declaration of Helsinki.

**Catheterisation**

To measure small intestinal ammonia release, immediately after TIPS construction or after TIPS angiography, the tip of a 5F multipurpose angiographic catheter was placed in the superior mesenteric vein, 3–4 cm before the junction with the splenic vein, and left in situ until the end of the study. During the study and subsequent angiographic studies there was no evidence of thrombotic sequelae from mesenteric venous catheterisation. An indwelling catheter (LeaderCath, Vygon, 115/09, 20G, 8 cm, 0.6–0.9 mm) was placed in the left radial artery. All catheters were rinsed with sterile saline between sampling. A fine bore nasoduodenal tube (Frekasoft 8F, Fresenius, Erlangen, Germany) was inserted under fluoroscopic control immediately before the angiographic procedure and controlled for correct position afterwards.

**Medication**

During the TIPS procedure, fentanyl or alfentanil was given for analgesia and midazolam for sedation. Immediately after TIPS, a bolus dose of heparin 5000 IU was given intravenously. After transfer to the metabolic ward a constant infusion of heparin was given at a rate necessary to prolong the activated prothrombin time to no more than twofold.

**Nutrition Protocols**

All patients received a carbohydrate-fat mixture (Super Soluble Duocal, Scientific Hospitals Supply, Heilbronn, Germany) containing carbohydrate 182 g/l, fat 56 g/l, and NaCl 170 mmol/l via the nasoduodenal tube at a rate of 2.0 ml/kg/h (equivalent to 175 kcal/h over 120 minutes). The mixture was given to provide caloric substrates and to maintain hormonal responses and mucosal perfusion comparable with the postprandial situation in both groups. In the enteral group (n=8), this mixture also contained a glutamine fortified amino acid solution (Glamix, Pharmacia and Upjohn, Erlangen, Germany). This solution was chosen because of its high content of ammoniagenic amino acid glycine and glutamine.23 In the parenteral group (n=8), an identical amino acid solution was infused via a central venous line at an identical rate (glutamine 274 µmol/kg/h). Thus all patients received carbohydrate and fat isoenergetically by duodenal infusion while amino acids were given as an isonitrogenous infusion either by the enteral or parenteral route (fig 1). Patients were not allowed food or drinks other than plain water until the end of the study.

**Blood Sampling**

Blood was sampled in containers with either Li-heparin (amino acids) or K$_2$-EDTA (ammonia) in triplicate at baseline (−10, −5, and 0 minutes) and at 15, 30, 60, 90, 120, 180, and 240 minutes after the start of the infusion of nutrients. Sealed containers at 4°C were immediately transferred to the laboratory for centrifugation and deproteinisation (amino acids) or determination of ammonia. After deproteinisation, amino acid samples were kept at −80°C until analysis.

**Analytical Methods**

Ammonia was measured in plasma using an automated enzymatic test.24 Amino acid concentrations in plasma were measured by reversed phase high performance liquid chromatography with fluorescence detection after precolumn derivatisation with OPA.25

---

**Table 1 Patient characteristics (mean (SEM) or number)**

<table>
<thead>
<tr>
<th></th>
<th>Enteral (n=8)</th>
<th>Parenteral (n=8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>40.0 (2.4)</td>
<td>48.9 (3.1)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>83.0 (4.9)</td>
<td>76.0 (2.0)</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>182 (2)</td>
<td>176 (2)</td>
</tr>
<tr>
<td>Aetiology of cirrhosis (ALD/PBC)</td>
<td>8/0</td>
<td>7/1</td>
</tr>
<tr>
<td>Child-Pugh score</td>
<td>6.25 (0.52)</td>
<td>6.75 (0.68)</td>
</tr>
<tr>
<td>Classification (A/B/C)</td>
<td>5/3/0</td>
<td>4/3/1</td>
</tr>
<tr>
<td>Portocaval pressure gradient</td>
<td>23.2 (0.9)</td>
<td>27.3 (1.2)</td>
</tr>
<tr>
<td>Post-TIPS (mm Hg)</td>
<td>13.8 (1.4)</td>
<td>14.0 (2.0)</td>
</tr>
</tbody>
</table>

ALD, alcoholic liver disease, PBC, primary biliary cirrhosis.
No significant differences between groups.
CALCULATIONS AND STATISTICAL ANALYSIS
Substrate concentration differences were calculated as mesenteric venous-arterial concentration differences. Accordingly, negative values indicate net uptake and positive values net release. Substrate exchange was calculated as area under the curve of the venous-arterial differences for the baseline period and for 61–120 minutes of amino acid infusion. Systemic ammonaemia and glutaminaemia or portal availability and load were calculated as area under the curve of increments in arterial or mesenteric venous concentrations above baseline. All data are given as mean (SEM). Statistical significance was performed by two tailed t test for paired or unpaired samples using Bonferroni's correction where appropriate. Venous-arterial differences were analysed for difference from zero using the two tailed Wilcoxon signed rank test for matched pairs. Data analysis was performed using Excel and SPSS on a personal computer. Results were regarded as significant at the 0.05 level.

Results

POST-ABSORPTIVE STATE
Before infusions of amino acids (AA), plasma levels of ammonia and glutamine in samples from the artery or mesenteric vein were not different between groups. However, the arterial ammonia level was elevated above normal (55 (3) v 19 (1) µmol/l; n=16 each; p<0.001). Ammonia was released from the intestine with positive concentration differences between the superior mesenteric vein (SMV) and artery (61 (6) µmol/l; p<0.001). Glutamine was extracted by the intestine (ASMV-arterial −91 (13) µmol/l; p=0.003), equivalent to a fractional extraction rate of 24%.

EFFECT OF AMINO ACID INFUSION ON AMMONIA
During enteral AA infusion, arterial ammonia levels increased from 60 (4) µmol/l to maximal values of 157 (12) µmol/l at 120 minutes (p<0.001) and returned to 74 (7) µmol/l at 240 minutes (fig 2A). During parenteral AA infusion, however, there was a continuous but slow rise in arterial ammonia levels, reaching maximal values at 120 minutes (115 (12) µmol/l; p=0.036 for parenteral v enteral) (fig 3A). This resulted in a significantly (p=0.033) higher degree of systemic hyperammonaemia during enteral than parenteral AA infusion (fig 4).

This increase in systemic hyperammonaemia was associated with a significant rise in mesenteric venous-arterial differences across

Figure 2  Enteral amino acid infusion. Ammonia (A) and glutamine (B) concentrations before, during (0–120 minutes), and after enteral infusion. Arterial and superior mesenteric venous (SMV) concentrations are mean (SEM).

Figure 3  Parenteral amino acid infusion. Ammonia (A) and glutamine (B) concentrations before, during (0–120 minutes), and after parenteral infusion. Arterial and superior mesenteric venous (SMV) concentrations are mean (SEM).

Figure 4  Degree of systemic hyperammonaemia and systemic availability of glutamine following enteral (E) or parenteral (P) amino acid infusion. Values are calculated as area under the curve of increments in arterial substrate concentrations above baseline from 0 to 240 minutes. Error bars indicate SEM. *p<0.05, enteral v parenteral.
SMV drained viscera from 65 (9) to 107 (17) µmol/l (p=0.024) as early as 15 minutes after commencing enteral AA infusion (fig 5A). Mesenteric venous-arterial differences increased up to 166 (15) µmol/l at 120 minutes. After the end of AA infusions, ammonia release declined to near basal levels (70 (7) µmol/l) at 240 minutes. After parenteral AA infusion, however, ammonia release from SMV drained viscera increased only moderately from 50 (5) µmol/l at baseline to 62 (8) µmol/l at 15 minutes (NS), and to 85 (10) µmol/l at 120 minutes (p=0.013) (fig 5A).

As a result, there was a significant increase in net intestinal ammonia efflux when baseline and the terminal infusion periods were compared during enteral (p<0.001) and parenteral (p=0.009) AA infusions (fig 6A). However, the portal ammonia load was significantly (p=0.0014) higher during enteral than parenteral AA infusion (fig 7).

EFFECT OF AA INFUSION ON GLUTAMINE
To search for possible alterations in the intestinal utilisation of glutamine as the major metabolic precursor of ammonia, glutamine concentrations were measured. Arterial and mesenteric venous glutamine levels increased promptly after enteral AA infusions were started (fig 2B). Simultaneously, the intestine ceased to extract glutamine from arterial blood and switched to release glutamine (mesenteric venous-arterial difference −100 (19) µmol/l at baseline v 31 (40) µmol/l at 120 minutes; p=0.028). After enteral AA infusions were stopped, however, the intestine returned to extraction at 180 and 240 minutes (fig 5B).

After parenteral AA infusion, arterial levels of glutamine increased (370 (28) v 628 (41) µmol/l at 120 minutes; p<0.001) to a similar degree as during enteral infusion (380 (28) v 559 (29) µmol/l at 120 minutes; p<0.01) (fig 3B). Despite the increase in arterial levels during enteral AA infusion, the mesenteric venous-arterial glutamine difference remained constant throughout (−66 (12) v −68 (18) µmol/l at 120 minutes; NS).

During enteral infusions, intestinal net glutamine exchange changed from uptake to release (p=0.008) but remained unaltered during parenteral infusion (fig 6B). Thus portal glutamine availability was higher (p=0.048) during enteral AA infusion (fig 7). Interestingly, the degree of arterial glutaminemia, expressed as area under the curve of increments in arterial concentrations above baseline (fig 8B), was significantly lower during parenteral than enteral AA infusion (fig 8A).
Post-feeding hyperammonaemia

Discussion

The beneficial effects of TIPS in the control of variceal haemorrhage or ascites are associated with an increased risk of hepatic encephalopathy. We used TIPS to obtain mesenteric venous blood for selective measurement of intestinal ammonia release to study intestinal ammonia efflux and glutamine metabolism in the post-absorptive state, and during and after isonitrogenous enteral or parenteral infusion of amino acids.

Using this approach we obtained data supporting the view of the small intestine as a source of post-feeding hyperammonaemia in liver cirrhosis. Furthermore, in patients with cirrhosis and TIPS, enteral nutrition appeared to be associated with a higher degree of systemic hyperammonaemia than isonitrogenous parenteral nutrition. Finally, enteral and parenteral infusions of the same glutamine containing solution were associated with similar increases in arterial glutamine concentrations despite high first pass metabolism of glutamine in the intestine.

To verify the small intestine as a source of post-feeding hyperammonaemia, we chose a kinetic approach and measured ammonia efflux of SMV drained viscera after enteral or parenteral AA infusion. The rapid and significant increase in ammonia release from SMV drained viscera even at 15 minutes after commencing enteral AA infusions makes the small intestine the most likely site of this increase in mesenteric venous ammonia. This view is supported by the findings of van der Hulst and colleagues who demonstrated that glutamine uptake and ammonia release were much higher in the jejunum than in the ileum or colon. As no patient had abdominal symptoms or frank diarrhoea, and gastrointestinal transit may even be slowed as a result of sedation and cirrhosis, it is unlikely that the observed rapid increase could have resulted from colonic bacterial metabolism of infused nutrients. In addition, small intestinal bacterial overgrowth that may be present in patients with liver cirrhosis should have been eliminated by the decontamination protocol. The important findings of intestinal ammonia efflux and the degree of systemic hyperammonaemia being higher in the enteral than in the parenteral group were also confirmed when a separate analysis was performed for patients studied on the day of TIPS placement and those studied at elective TIPS portography.

Although we chose a substantial nitrogen load of 40.5 g of amino acids/75 kg body weight within 120 minutes (analogous to protein test meals in cirrhotics) none of our patients had worsening of their mental state and this has been confirmed in a subsequent study using psychometric tests. This finding merits particular attention as glutamine accounted for 5.9 g (14.5%) of the total amino acid load and has been regarded as more ammoniagenic than other amino acids and capable of inducing encephalopathy. Our findings are in agreement with the observation that protein intolerant patients with cirrhosis and truly mal fed induced encephalopathy episodes are rather the exception than the rule and therefore protein restriction should be reserved for this minority of patients. In the light of our findings and a recent hypothesis, the question of glutamine as a potentially essential parenteral nutrient in malnourished cirrhotic patients deserves further clarification.

Interestingly, in terms of hyperammonaemia, parenteral amino acid infusion was clearly superior to enteral amino acid infusion in patients with cirrhosis, as shown by the significantly lower degree of arterial hyperammonaemia. This finding is even more remarkable considering that systemic availability of free glutamine, as measured by the degree of arterial glutaminaemia during enteral infusion, was no less than during isonitrogenous parenteral AA infusion. The potential for systemic hyperammonaemia may be expressed as a risk (hyperammonaemia)/benefit (glutaminaemia) ratio of the AUC of increments in arterial ammonia over the AUC of increments in arterial glutamine. Using this expression, parenteral AA infusion was associated with a lower risk/benefit ratio of 0.26 (0.03) vs 0.59 (0.16).

The significant increase in systemic ammonia load during enteral AA infusion appeared to be a result of efficient intestinal first pass metabolism of glutamine and the fact that all administered glutamine must pass these straits before entering the systemic circulation; during parenteral infusion, glutamine is distributed to all tissues of the body. This may provide one explanation for the well known observation that parenteral nutrition using standard amino acids is generally well tolerated in patients with cirrhosis. Moreover, the difficulties of demonstrating a clinical advantage of solutions enriched in branched chain amino acids compared with standard solutions may result from the low potential of standard solutions to cause arterial hyperammonaemia in control groups.

A second therapeutic implication of our findings concerns malabsorption or even small bowel evacuation as a likely common denominator regarding the mechanism of many different empirical strategies in the treatment of acute hepatic encephalopathy. Magnesium sulphate, sorbitol or disaccharides (among other modes of action) are potent osmotic laxatives. Neomycin in therapeutic doses has been shown to impair the structure and enzyme activity of enterocytes causing malabsorption. Therefore, our data suggest that after gastrointestinal haemorrhage, blood should be cleared not only from the colon but also from the small intestine to remove this substrate for small intestinal metabolic ammonia generation and to avoid its unfavourable effect on intestinal protein metabolism.

To our knowledge, this is the first study to measure amino acid absorption by assessment of mesenteric venous substrate activity in humans. Despite extensive metabolism by small intestinal enterocytes, a net mesenteric venous appearance of glutamine
was demonstrated during the last 40 minutes of enteral AA infusion. Visual assessment of mesenteric venous-arterial concentration differences (fig 5A, B) suggests that glutamine uptake from the lumen was of the same magnitude as the increase in ammonia release from SMV drained viscera during enteral AA infusion. This impression is supported by calculating substrate net exchange using the area under the curve method for mesenteric venous-arterial concentration differences (fig 6). However, tracer studies are needed to draw more definite conclusions on the precise stoichiometry of ammonia production and more definite conclusions on the precise availability of free glutamine and peak arterial levels were not different between groups. This finding indicates that, at least in patients with liver cirrhosis and portal systemic shunting, isonitrogenous infusion regimens produce similar systemic substrate availability regardless of the route of provision (enteral or parenteral).

Clearly, interpretation of our mesenteric venous-arterial difference data would be strengthened by a valid measurement of mesenteric venous blood flow, which at present is a technically unsolved problem,20 despite the possibility that intestinal perfusion may have been different between the entire groups, this potential error was minimised as both groups received the same enteral carbohydrate and fat load to induce comparable changes in absorption induced mucosal perfusion and insulin response. Despite these limitations, the pronounced difference between groups in intestinal uptake or release of glutamine and intestinal release of ammonia clearly demonstrates that enteral AA infusion was associated with significant glutamine absorption and a greater increase in small intestinal ammonia efflux.

In conclusion, our findings support the hypothesis that in the absorptive state, glutamine metabolism of the small intestine is a source of increased portal ammonia concentrations and that post-feeding hyperammonaemia is caused at least in part, by small intestinal ammonia release. Therefore, antihyperammonaemic strategies should take this into account, as exemplified by orthograde intestinal lavage.21 In cirrhotic patients with TIPS, enteral feeding may carry a higher risk of hyperammonaemia than parenteral feeding and should not be regarded as superior to parenteral feeding per se.

Cost of amino acid analyses were, in part, covered by a research grant from Pharmacia and Upjohn.

14 Nolte W, Wittfang J, Schindler C, et al. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic stent-shunt in patients with cirrhosis: Clinical, labora-
25 Roth E, Karner J, Ollenschläger G, et al. Alanylglutamine reduces muscle mass loss of alanine and glutamine in post-
26 Jalan R, Forrest EH, Stanley AJ, et al. Randomized trial comparing transjugular intrahepatic portosystemic stent-
27 van Thielt DH, Fagiuoli S, Wright HT, et al. Gastrointestinal transit in cirrhotic patients: effects of hepatic encephalop-